462 related articles for article (PubMed ID: 29743019)
1. Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients.
Pacho C; Domingo M; Núñez R; Lupón J; Núñez J; Barallat J; Moliner P; de Antonio M; Santesmases J; Cediel G; Roura S; Pastor MC; Tor J; Bayes-Genis A
BMC Geriatr; 2018 May; 18(1):109. PubMed ID: 29743019
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
[TBL] [Abstract][Full Text] [Related]
3. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).
Stienen S; Salah K; Moons AH; Bakx AL; van Pol P; Kortz RAM; Ferreira JP; Marques I; Schroeder-Tanka JM; Keijer JT; Bayés-Genis A; Tijssen JGP; Pinto YM; Kok WE
Circulation; 2018 Apr; 137(16):1671-1683. PubMed ID: 29242350
[TBL] [Abstract][Full Text] [Related]
4. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.
Davarzani N; Sanders-van Wijk S; Karel J; Maeder MT; Leibundgut G; Gutmann M; Pfisterer ME; Rickenbacher P; Peeters R; Brunner-la Rocca HP
J Card Fail; 2017 May; 23(5):382-389. PubMed ID: 28232046
[TBL] [Abstract][Full Text] [Related]
5. Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure.
Núñez J; Núñez E; Bayés-Genís A; Fonarow GC; Miñana G; Bodí V; Pascual-Figal D; Santas E; Garcia-Blas S; Chorro FJ; Rizopoulos D; Sanchis J
Eur Heart J Acute Cardiovasc Care; 2017 Dec; 6(8):685-696. PubMed ID: 27199489
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
[TBL] [Abstract][Full Text] [Related]
8. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure.
van Vark LC; Lesman-Leegte I; Baart SJ; Postmus D; Pinto YM; Orsel JG; Westenbrink BD; Brunner-la Rocca HP; van Miltenburg AJM; Boersma E; Hillege HL; Akkerhuis KM;
J Am Coll Cardiol; 2017 Nov; 70(19):2378-2388. PubMed ID: 29096809
[TBL] [Abstract][Full Text] [Related]
10. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.
Lupón J; de Antonio M; Galán A; Vila J; Zamora E; Urrutia A; Bayes-Genis A
Mayo Clin Proc; 2013 Mar; 88(3):234-43. PubMed ID: 23384388
[TBL] [Abstract][Full Text] [Related]
11. Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register.
Eriksson B; Wändell P; Dahlström U; Näsman P; Lund LH; Edner M
Scand J Prim Health Care; 2019 Dec; 37(4):434-443. PubMed ID: 31724475
[No Abstract] [Full Text] [Related]
12. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
[TBL] [Abstract][Full Text] [Related]
14. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
[TBL] [Abstract][Full Text] [Related]
15. Impact of diabetes on the predictive value of heart failure biomarkers.
Alonso N; Lupón J; Barallat J; de Antonio M; Domingo M; Zamora E; Moliner P; Galán A; Santesmases J; Pastor C; Mauricio D; Bayes-Genis A
Cardiovasc Diabetol; 2016 Nov; 15(1):151. PubMed ID: 27809845
[TBL] [Abstract][Full Text] [Related]
16. Assessment of a multi-marker risk score for predicting cause-specific mortality at three years in older patients with heart failure and reduced ejection fraction.
Bjurman C; Holmström A; Petzold M; Hammarsten O; Fu ML
Cardiol J; 2015; 22(1):31-6. PubMed ID: 24526512
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of carbohydrate antigen 125 in combination with N-terminal pro-brain natriuretic peptide in patients with acute decompensated heart failure.
Yoon JY; Yang DH; Cho HJ; Kim NK; Kim CY; Son J; Roh JH; Jang SY; Bae MH; Lee JH; Park HS; Cho Y; Chae SC
Korean J Intern Med; 2019 Jul; 34(4):811-818. PubMed ID: 30616330
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of PRIMA II: A multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-PRoBNP target on the reduction of readmIssion and Mortality rAtes.
Stienen S; Salah K; Moons AH; Bakx AL; van Pol PE; Schroeder-Tanka JM; Voogel AJ; Keijer JT; Kortz RA; Dickhoff C; Meregalli PG; Tijssen JG; Pinto YM; Kok WE
Am Heart J; 2014 Jul; 168(1):30-6. PubMed ID: 24952857
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.
Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121
[TBL] [Abstract][Full Text] [Related]
20. NTproBNP and ST2 as predictors for all-cause and cardiovascular mortality in elderly patients with symptoms suggestive for heart failure.
Boman K; Thormark Fröst F; Bergman AR; Olofsson M
Biomarkers; 2018; 23(4):373-379. PubMed ID: 29355441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
